Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone + goserelin
- Development stage
- Unknown
- Lead developer
- University of Cologne
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous, Implant
01
Overview
This drug combination consists of the BEACOPP chemotherapy regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) administered alongside goserelin, a gonadotropin-releasing hormone (GnRH) agonist. BEACOPP is a standard-of-care intensive chemotherapy regimen developed by the German Hodgkin's Lymphoma Study Group for advanced-stage Hodgkin Lymphoma. Goserelin is added to this regimen specifically to suppress ovarian function during treatment, aiming to protect the ovarian reserve and reduce chemotherapy-induced ovarian toxicity in fertile female patients. The regimen targets multiple pathways, including DNA replication, microtubule assembly, and the pituitary-gonadal axis.
- Other names
- BEACOPP + goserelinBEACOPP plus goserelin
02
Targets
TOP2A (DNA topoisomerase II)GnRHR (Gonadotropin-releasing hormone receptor)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone + goserelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone + goserelin.